Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2009

View Archived Issues

Recent Georgia Tech patent describes novel HDAC inhibitors

New MAPKAP-K2 (MK2) inhibitors reported in recent Novartis patent

Combination of YM-155, docetaxel and prednisone used in prostate cancer therapy

BIBF-1120 and BIBW-2992 may be used in combination in prostate cancer treatment

Bayer discloses prodrugs of apixaban for thromboembolic disorders

Merck & Co. discloses novel orexin receptor antagonists for insomnia

New HCV NS3/NS4 protease inhibitors reported in recent Gilead patent

PharmaMar licenses kahalalide F analogues to Marinomed

Catalyst halts enrollment into phase II trial of CPP-109 for methamphetamine addiction

MMI presents update on clinical development of GVX-3322 and ONCO-4417

2008 highlights at Elan

Anacor reports encouraging results from phase I AN-2718 trial

Pharmexa and Affitech enter into conditional merger agreement

MDV-3100 displays safety and antitumor activity in phase I/II trial for prostate cancer

Vertex to acquire ViroChem and its preclinical-stage polymerase inhibitors

FDA gives positive review of InNexus' IND plans for DXL-625 in NHL and CLL

Dronedarone reduces risk of hospitalization from cardiovascular events in atrial fibrillation

Meropenem/clavulanate combination inhibits extensively drug-resistant tuberculosis

Ferring launches degarelix for advanced prostate cancer

Quest presents positive results for its photosensitizer SL-052

4SC initiates phase IIa trial for 4SC-101 in Crohn's disease

Access announces results from a phase II ovarian cancer trial of ProLindac

CV Therapeutics reports phase I proof-of-concept data for CVT-3619

GlaxoSmithKline submits MAA for pazopanib in advanced kidney cancer

NICE refuses funding for advanced breast cancer treatment, Tyverb

Proteon initiates phase I/II PRT-201 study in hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...